论文部分内容阅读
目的 探讨应用脂质体介导血管抑制素 (angiostatin ,AG)基因治疗实验性人胰腺癌细胞系SW1990的价值。方法 血管抑制素AG基因被定向克隆入真核表达载体 pRC/CMV中。运用脂质体将重组体 pRC/CMV AG转入胰腺癌细胞系SW 1990中 ,进行抗肿瘤研究。 结果 构建的真核表达载体pRC/CMV AG经酶切证实正确。Westernblot和药敏试验均证实血管抑制素基因已整合到靶细胞DNA中并可分泌表达AG ,且可抑制血管内皮细胞的生长。动物模型显示 ,所构建的载体能在肿瘤内表达 ,且可有效抑制荷瘤裸鼠人胰腺癌细胞的微血管形成及肿瘤生长。结论 脂质体介导的重组体pRC/CMV AG有体内治疗胰腺癌的作用 ,可作为胰腺癌基因治疗的可能方法之一
Objective To investigate the value of liposome-mediated angiostatin (AG) gene therapy in treating human pancreatic cancer cell line SW1990. Methods The angiocidin AG gene was cloned into eukaryotic expression vector pRC/CMV. The recombinant pRC/CMV AG was transferred into the pancreatic cancer cell line SW1990 using liposomes for antitumor studies. Results The constructed eukaryotic expression vector pRC/CMV AG was verified by enzyme digestion. Westernblot and susceptibility tests all confirmed that the angiostatin gene has been integrated into the target cell DNA and can secrete and express AG, and can inhibit the growth of vascular endothelial cells. The animal model showed that the constructed vector can be expressed in the tumor and can effectively inhibit the microvessel formation and tumor growth of human pancreatic cancer cells in a tumor-bearing nude mouse. Conclusion Liposome-mediated recombinant pRC/CMV AG has the effect of treating pancreatic cancer in vivo and may be used as one of possible methods for gene therapy of pancreatic cancer.